IMMUCan project progress - Work Package Overview
The project partners of IMI IMMUCan are progressing well four months into the project since the launch. Find below an update from each Work Package.
WP1 “Project Coordination”: the Grant Agreement and the Consortium Agreement have been signed by all partners. Each partner organisation will receive soon one original signed copy of the consortium agreement. The Grant Agreement is available from the “Document Library” section of the EU portal. Public partners should receive the pre-payment in July. The SharePoint project is being revamped and the new version would be available in July.
WP2 “Dissemination”: the logo proposed by KUL was selected and should be used for all communication. We are currently working on the project website. We expect to have it online at the end of summer 2019. There will be one section for researchers and another for lay people. Information for 3rd parties on how to contribute to the project will be available.
WP3 “Legal”: the Data Protection Impact Assessment is in progress. The focus is currently on partners such as SIB, CHUV and UoZ that will act as data processors on behalf of EORTC. The draft IMMUcan policy for access to project data and HBM was circulated. The next step will be the preparation of the template MTA clinical for project access to partners or 3rd parties study material.
WP4.1 “Broad profiling”: the contract with CeGat, the broad profiling service provider, has been fully executed. The HBM and the data flows are operational. The first version of the molecular report generation pipeline is ready to process genomic data (WES and RNAseq). This is a critical piece since it is the main incentive for clinicians and patients to participate to the project. The three immunofluorescence panels 1, 2 and 3 are now final. The imaging mass cytometry panel is also final. Final testing of the workflow, including the control samples, is underway.
WP4.2 “Deep profiling”: the single cells sequencing strategy is being discussed for the H&N cohort. The liquid CytOF and FACS panel for blood analysis is being finalized. How to analyze ctDNA, especially for lung cancer patients still needs to be specified.
WP5 “Access to patient material”: as of June 2019, 107 EORTC clinical sites are interested in IMMUCan. Since 27 May, 40 clinical sites are authorized in SPECTA for patient recruitment. Eights patients (6 NSCLC and 2 GU) were registered in SPECTA as of June 2019. HBM availability and medical eligibility is being checked for inclusion of these patients into IMMUcan. The EORTC is considering several measures including site initiation visits for boosting clinical sites interest. The SPECTA patient Informed Consent Form needs to be amended to include the collection of stool and saliva. This would be completed latest by January 2020 including the approval by Ethics Committees. Until then, only tissue and blood samples will be collected. Two clinical studies (EORTC 1559 UPSTREAM and DUTRALESCO KUL) both in H&N cancers are approved to be included in the project.
WP6 “Biomarker validation” is busy drafting a “Rule Book” on how to submit hypothesis for prospective biomarker validation, how to access project data and how to refer to the various data elements. The Rule Book is expected to be ready by end of July.
WP7 “Bioinformatics” has started the monthly TC. The work has started with activities on Layer 0 “meta-analysis and mining of public data”.
WP8 “Data platform”: the project IT infrastructure managed by SIB is ready to process, store and provide access to data. The web platform, firewall and database are in place. The authentication service for data access is being organized with partners.
The Project Coordination Team